Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Respons på fremvoksende antimikrobiell resistens med inneslutningsmikrobiotaterapi (REACT)

3. november 2026 oppdatert av: Michael Woodworth, Emory University

Respons på fremvoksende antimikrobiell resistens med inneslutningsmikrobiotaterapi

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO) in patients admitted to long-term care facilities. REACT is designed to test the safety and efficacy of instillation of donor intestinal microbiota.

Patients admitted to long-term care facilities (e.g. long-term acute care hospitals and ventilator-capable skilled nursing facilities) found to be MDRO colonized during prevalence screening activities performed in the related APPS study.

Facilities undergo prevalence sampling that involves participant peri-rectal, inguinal, and stool sampling to estimate the prevalence of targeted MDROs (CRE, ESBL, VRE, MDRP) under the accompanying APPS protocol. Patients who are positive with at least one targeted MDRO are eligible for an Emory manufactured MT product (via rectal enema or feeding tube), or observation followed by repeat sampling at Days 7, 14, 21, and 28. Participants will be followed with collection of data on adverse events/safety/changes in medications at Days 0, 7, 14, 21, 28, and followed up once a month for 6 months, after MT administration.

Studietype

Intervensjonell

Registrering (Faktiske)

58

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Georgia
      • Atlanta, Georgia, Forente stater, 30329
        • A.G Rhodes Wesley Woods
      • Decatur, Georgia, Forente stater, 30030
        • Emory Long Term Acute Care (LTAC)
    • Illinois
      • Hinsdale, Illinois, Forente stater, 60521
        • RML Specialty Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19146
        • Penn Medicine Rittenhouse

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Be able (or have available a Legal Authorized Representative who is able) to understand and sign a written informed consent document.
  2. Be at least 18 years old at the time of consent.
  3. Be able to comply with all study protocol requirements, including able to receive MT as retention enema or via enteral feeding tube and be available for the duration of the study follow up.
  4. Be colonized with a target MDRO (CRE, VRE, ESBL, MDR Pseudomonas) as detected by bacterial culture of stool or peri-rectal swab (collected in companion APPS facility prevalence sampling protocol).
  5. Be able to discontinue or complete planned courses of antibiotics, probiotics, and other microbiota restoration therapies by Day -1 and not resume until after Day 28.
  6. The effects of the MT on the developing human fetus are unknown. For this reason, persons of child-bearing potential (POCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  7. Agree to refrain from receptive anal intercourse until the last biological specimen (stool sample or peri-rectal swab) is collected (Day 28).

Exclusion Criteria:

  1. Are pregnant, breastfeeding, lactating, or planning a pregnancy during study duration (through 4 weeks after the last dose of investigational product, or MT), if POCBP.

  2. Have known uncontrolled intercurrent illness(es):

    1. Symptomatic congestive heart failure
    2. Acute coronary syndrome
    3. Cardiac arrhythmia
    4. Untreated in-situ colorectal cancer
    5. Toxic megacolon
    6. Ileus
    7. Positive stool studies without completion of treatment course (including ova and parasites, Salmonella spp, Shigella, Campylobacter, and other enteropathogens).
    8. other acute illness that in the opinion of the investigator could affect the safety of the participant or make study data uninterpretable.
  3. Are on systemic antibiotics for any reason other than treatment of recent MDRO infection or clear anticipated need for antibiotics during the follow up period that cannot be rescheduled (e.g. fluoroquinolone prophylaxis for percutaneous nephrostomy tube exchange, prolonged antibiotic course for endocarditis). Participants must complete the planned antibiotic course by study Day -1.

  4. Have a compromised immune system, defined as:

    1. AIDS with CD4+ T-cell count <200 and detectable HIV viral load on most recent assay.
    2. Absolute neutrophil count (ANC) <1,000 neutrophils / mL on day of enrollment.
    3. Active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment within 2 months prior to enrollment.
    4. History of hematopoietic cell transplantation, either allogeneic or autologous in the last 1 year.
  5. Have a history of significant food allergy that led to anaphylaxis or hospitalization.

  6. Have a life expectancy of 24 weeks or less

  7. Have any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to:

    1. Known active intravenous drug or alcohol abuse
    2. Uncontrolled psychiatric illness
    3. Social situations (e.g. incarceration)
  8. Received an interventional agent (drug, device, or procedure) within 28 days prior to enrollment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Group 1: microbiota therapy (MT)

Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition).

Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.

Andre navn:
  • Fekal mikrobiotatransplantasjon (FMT)
  • Mikrobiom terapeutisk (MT)
  • Avføring fra friske givere i saltvannssuspensjon med 9 volumprosent glyserol
Ingen inngripen: Group 2: Observation

Group 2 will be assigned to observation.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Difference in number of solicited Adverse Events (AEs)
Tidsramme: Day 0, Day 7 post-intervention

Difference in number of solicited AEs between Day 0 and Day 7 in AMG-treated vs Observation participants.

Day 0, Day 7 post-intervention
Difference in severity of solicited AEs
Tidsramme: Day 0, Day 7 post-intervention

Difference in severity of solicited AEs will be compared in AMG-treated vs Observation participants. Graded as mild, moderate or severe, up to 7 days post-intervention.

Day 0, Day 7 post-intervention
Difference in number of unsolicited AEs
Tidsramme: Day 0, Day 28 post-intervention

Difference in number of unsolicited AEs between Day 0 and Day 28 in AMG-treated vs Observation participants.

Day 0, Day 28 post-intervention
Difference in severity of unsolicited AEs
Tidsramme: Day 0 and Day 28

Difference in severity of unsolicited AEs will be collected between Day 0 and Day 28. Graded as mild, moderate or severe and compared in AMG-treated vs Observation participants

Day 0 and Day 28
Number of participants by composite MDRO Colonization and survival status
Tidsramme: Day 28 post-intervention

Participants will be classified into one of three ordinal categories: (1) alive without MDRO colonization, (2) alive with MDRO colonization, or (3) deceased. MDRO colonization is defined as a stool culture at Day 28 positive for any target multidrug-resistant organism (MDRO).

Day 28 post-intervention

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Count of serious AEs (SAEs)
Tidsramme: Day 180 (6 months)

Count of serious AEs (SAEs) between Day 0 and Month 6 (Day 180) censored by last telephone visits or death, whichever is later.

Day 180 (6 months)
Count of AEs of Special Interest (AESIs)
Tidsramme: Day 180 (6 months)

Count of AEs of Special Interest (AESIs) at day Day 180, censored by last telephone visit or death, whichever is later.

Day 180 (6 months)
Number of participants by category-specific MDRO Colonization and survival status
Tidsramme: Day 28

Participants will be classified into one of three ordinal categories: (1) survival without colonization of the category-specific multidrug-resistant organism (MDRO), (2) survival with colonization of the category-specific MDRO, or (3) deceased. Category-specific MDRO colonization is defined as a stool culture at Day 28 positive for the category-specific MDRO being evaluated (e.g., ESBL, CRE, MDRP, or VRE).

Day 28

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Michael Woodworth, MD, Emory University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. januar 2025

Primær fullføring (Faktiske)

8. juli 2026

Studiet fullført (Antatt)

1. januar 2027

Datoer for studieregistrering

Først innsendt

13. mars 2024

Først innsendt som oppfylte QC-kriteriene

13. mars 2024

Først lagt ut (Faktiske)

20. mars 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • STUDY00007230
  • U54CK000601 (U.S. NIH-stipend/kontrakt)
  • 2024P008055 (Annen identifikator: Emory IRB)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified participant solicited adverse event and serious adverse event data will be shared.

Isolate genomic data and participant metagenomic data will be shared in public repositories (NCBI) at time of publication

IPD-delingstidsramme

Data will become available at time of publication.

Tilgangskriterier for IPD-deling

Sequence data access will not be restricted. Additional participant-level data will be shared by review of PI of proposing investigators and appropriate ethical approval (e.g. IRB) if any.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere